Treatment and outcomes for early-stage non-small cell lung cancer in China

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multi-center chart review will extract medical record data from participating hospitals in China to describe initial treatment patterns, biomarker testing, and clinical outcomes for adults with stage I–III NSCLC. Patients diagnosed in specified windows (May–Dec 2025, May–Dec 2026, or May–Dec 2027) who meet inclusion criteria will be included and relevant data such as staging, treatments, biomarker results, and follow-up will be collected. Analyses will compare patterns over time and across centers to characterize changes in standard-of-care and use of selected regimens. No interventional therapies are given as part of this observational review.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Stage I-III at initial NSCLC diagnosis
* Aged ≥18 years at first diagnosis of NSCLC
* Timeframe of NSCLC diagnosis:

For DE1: diagnosed with NSCLC during the period between May 1st 2025 and December 31st 2025 For DE2: diagnosed with NSCLC during the period between May 1st 2026 and December 31st 2026 For DE3: diagnosed with NSCLC during the period between May 1st 2027 and December 31st 2027

Exclusion Criteria:

* NSCLC is not the primary cancer diagnosis
* Patients with a recent history of other tumor or concurrent other tumor
* Patients participating in interventional clinical trials at time of initial diagnosis
* Patients with positive pregnancy status at the time of diagnosis

Where it's running

• Research Site
  Beijing, China Recruiting

Study contacts

• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Phase 1 of PF-08046033 for advanced non-small-cell lung cancer, esophageal squamous cell cancer, and cutaneous melanoma

  This Phase 1 study will try the experimental antibody-drug conjugate PF-08046033 in adults whose non-small-cell lung cancer, esophageal squamous cell cancer, or cutaneous melanoma has progressed after standard treatments.

  Recruiting at 20 sites Phase 1 Pfizer · Denver, Colorado and 20 other locations · NCT07519655

• PF-08634404 Alone or with chemotherapy in early-stage or locally advanced NSCLC

  This study tests PF-08634404 by itself or with chemotherapy in adults with early-stage or locally advanced non-small cell lung cancer that may be surgically removable or were candidates for additional therapy after initial treatment.

  Recruiting at 28 sites Phase 2 Pfizer · Huntsville, Alabama and 36 other locations · NCT07489066

• EPI-326 for EGFR-mutant non-small cell lung cancer and head and neck squamous cell carcinoma

  This phase 1 trial will try EPI-326, a new drug, in people with EGFR-mutant non‑small cell lung cancer or advanced head and neck squamous cell carcinoma to find safe doses, study how the body handles it, and look for early signs it shrinks tumors.

  Recruiting at 8 sites Phase 1 EpiBiologics · Los Angeles, California and 7 other locations · NCT07462377

• Evaluating a new CAR T-cell therapy for solid tumors expressing EGFR

  This study is testing a new CAR T-cell therapy to see if it can safely help adults with certain solid tumors, like colorectal and lung cancer, that have specific markers.

  Recruiting at 10 sites Phase 1/2 A2 Biotherapeutics Inc. · Gilbert, Arizona and 9 other locations · NCT06682793

• Evaluating AL8326 for advanced small cell lung cancer treatment

  This study is testing a new drug called AL8326 to see if it can help people with advanced small cell lung cancer who need a second treatment option.

  Recruiting at 5 sites Phase 2 Advenchen Laboratories, LLC · Birmingham, Alabama and 6 other locations · NCT05363280

• Patient-specific MRD liquid biopsy for resected NSCLC

  This study tests a personalized MRD blood and bronchial washing test after surgery to see if it can signal recurrence earlier in people with resected NSCLC.

  Recruiting Yonsei University · Yongin-si, Gyeonggi-do and 2 other locations · NCT07921888

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.